Every S-3 that Predictive Oncology Inc. (POAI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow POAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full POAI filings page.
Axe Compute Inc. filed a shelf registration to offer up to $1,000,000,000 of securities. The prospectus registers up to $1,000,000,000 of common stock, preferred stock, warrants, debt securities, units or subscription rights to be offered from time to time by prospectus supplement. The document discloses the Company’s Strategic Compute Reserve of approximately 6.197 billion ATH tokens valued at $29.1 million as of June 8, 2026, and an enterprise contract with an aggregate value of $260 million for a 36-month deployment of 2,304 NVIDIA B300 GPUs with targeted deployment beginning in Q3 2026. The prospectus describes governance, capital structure and distribution mechanics and states that net proceeds will be used for general corporate purposes, compute operations, infrastructure deployments and to grow the Strategic Compute Reserve.
Predictive Oncology Inc. is registering the resale of up to 5,970,181 shares of common stock by existing stockholders. These consist of 2,547,789 PIPE Shares issued in August and September 2025 private placements and 3,422,392 shares issuable upon exercise of various warrants, including pre-funded Cash PIPE Warrants, Agent Warrants and Advisor Warrants. The company is not selling any new shares in this offering and will not receive proceeds from stockholder resales, though it may receive cash if warrants are exercised.
The filing also details a major shift in strategy toward a digital asset treasury centered on Aethir tokens (ATH). As of November 19, 2025, the company held about 5.6 billion ATH valued at approximately $107 million, with 3.6 billion tokens locked and 2.0 billion unlocked. Extensive risk disclosures explain that concentrating treasury assets in ATH, using staking, DeFi and third-party asset managers, and operating in an evolving regulatory environment could create significant volatility in earnings, liquidity constraints and potential adverse impacts on the stock price.
Predictive Oncology Inc. filed a resale registration covering up to 5,970,181 shares of common stock, to be sold from time to time by the selling stockholders after effectiveness. The company is not offering any shares.
The registered amount includes 3,365,690 PIPE Shares issued in August and September private placements, plus 2,604,491 shares issuable upon warrant exercise, consisting of 1,037,250 Cash PIPE Warrant Shares, 218,335 Agent Warrant Shares, and 1,348,906 Advisor Warrant Shares.
No proceeds will go to the company from stockholder resales. The company would receive cash only upon warrant exercises. The Cash PIPE Warrants carry a nominal $0.01 per-share exercise price; Agent and Advisor Warrants are exercisable at $11.6265 per share. POAI trades on Nasdaq; the last reported price was $9.30 per share on October 21, 2025.
Predictive Oncology Inc. filed a resale registration covering up to 14,903,393 shares of common stock underlying pre-funded warrants issued under a September 29, 2025 securities purchase agreement. The shares may be sold from time to time by the selling stockholders named in the prospectus.
The company is not offering any shares and will not receive proceeds from sales by the selling stockholders; it would receive only any cash paid upon warrant exercise. The warrants carry a $0.01 per share exercise price, have no expiration, and include a 19.99% beneficial ownership limitation. Exercise of these warrants is subject to shareholder approval for the underlying share issuance.
As context, the company’s Nasdaq ticker is POAI, and the last reported sale price was $9.30 per share on October 21, 2025. The filing notes a recent 1-for-15 reverse stock split effective September 30, 2025, and outlines a separate cash PIPE and a crypto-funded PIPE that introduced these pre-funded warrants. The plan of distribution permits various sale methods by the selling holders.